AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2371034 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg twice daily)
Number of subjects: 17
Study 2371034 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 31555 — intervention group
Group type: EXPERIMENTAL
Intervention: Supristol (co-trifamole)
Number of subjects: 163
Study 31555 — intervention group
Group type: COMPARATOR
Intervention: co-trimoxazole
Number of subjects: 163
Study 30643648 — intervention group
Group type: EXPERIMENTAL
Intervention: Community perceptions towards pregnant women with disabilities (PWDs)
Number of subjects: 405
Study 30643648 — intervention group
Group type: COMPARATOR
Intervention: Educational status
Number of subjects: 405
Study 30643648 — intervention group
Group type: COMPARATOR
Intervention: Perceptions of disability causes
Number of subjects: 405
Study 26892333 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-delivered education/counseling intervention
Number of subjects: 4009
Study 26892333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4009
Study 24705623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol and probucol combination therapy
Number of subjects: 119
Study 24705623 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol monotherapy
Number of subjects: 119
Study 22089058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 260
Study 20043296 — intervention group
Group type: EXPERIMENTAL
Intervention: advanced practice nurse‐delivered, culturally tailored, in‐home psychotherapy intervention
Number of subjects: 80
Study 20043296 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 80
Study 19032525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (administered for 7-14 months)
Number of subjects: 8
Study 19032525 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 8
Study 15726857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with clinical recommendations from the sentinel system
Number of subjects: 39462
Study 15726857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with communicated recommendations
Number of subjects: 39462
Study 15726857 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire intervention group
Number of subjects: 39462
Study 15726857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cost
Number of subjects: 39462
Study 11238152 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer led programme for asthma education (Triple A Program)
Number of subjects: 272
Study 11238152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study 9512244 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (1H‐MRS) of metabolites in seminal plasma
Number of subjects: 0
Study 7852659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 209
Study 7852659 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 209
Study 3290711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 194
Study 3290711 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 194
Study 1984829 — intervention group
Group type: COMPARATOR
Intervention: 7-3 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3)
Number of subjects: 264
Study 1984829 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-3-7 therapy (cytarabine 100 mg/m2 on days 1 to 7 plus daunorubicin 50 mg/m2 on days 1 to 3 plus etoposide 75 mg/m2 on days 1 to 7)
Number of subjects: 264
Study 1984829 — intervention group
Group type: COMPARATOR
Intervention: 7-3 therapy
Number of subjects: 264
Study 1984829 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-3-7 therapy
Number of subjects: 264
Study 1984829 — intervention group
Group type: COMPARATOR
Intervention: 7-3 therapy (subset analysis for patients younger than 55 years)
Number of subjects: 264
Study 1984829 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-3-7 therapy (subset analysis for patients younger than 55 years)
Number of subjects: 264
Study 32044 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 20 mg
Number of subjects: 10
Study 32044 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 10
Study 32044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg
Number of subjects: 10
Study 32044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 3 mg
Number of subjects: 10
Study 32044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31710974 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time training program
Number of subjects: 534
Study 31710974 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention Medical Emergency Team call frequency
Number of subjects: 534
Study 31710974 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention Medical Emergency Team call frequency
Number of subjects: 534
Study 30507563 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Rehabilitation (SR)
Number of subjects: 30
Study 30507563 — intervention group
Group type: COMPARATOR
Intervention: Home-Based Rehabilitation (HBR)
Number of subjects: 30
Study 28739335 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized diet and physical exercise programme supervised by a dietician
Number of subjects: 41
Study 28739335 — intervention group
Group type: COMPARATOR
Intervention: No previous intervention (control group)
Number of subjects: 41
Study 26437449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dimensional and inter-sectoral intervention program including therapy simplification and individualized patient education during hospital stay and up to three months after discharge, with subsequent phone calls after discharge.
Number of subjects: 269
Study 26437449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dimensional and inter-sectoral intervention program
Number of subjects: 269
Study 26437449 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 269
Study 22856678 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing immediately after bleaching
Number of subjects: 80
Study 22856678 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing one hour after bleaching
Number of subjects: 80
Study 22856678 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing two hours after bleaching
Number of subjects: 80
Study 22856678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brushing after bleaching)
Number of subjects: 80
Study 21883123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg.kg(‐1)
Number of subjects: 60
Study 21883123 — intervention group
Group type: COMPARATOR
Intervention: Morphine 100 μg.kg(‐1)
Number of subjects: 60
Study 19609165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) training for 8 weeks, including 3 sets of daily fast and slow contractions in various positions and weekly motivational calls.
Number of subjects: 41
Study 19609165 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention or contact during the intervention period.
Number of subjects: 41
Study 17716312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial dose doxycycline (SDD; 20 mg bid)
Number of subjects: 128
Study 17716312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 14755150 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy (specifics not provided)
Number of subjects: 71
Study 14755150 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily for 12 months
Number of subjects: 71
Study 11580089 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP 14 in interview format
Number of subjects: 183
Study 11580089 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP 14 in questionnaire format
Number of subjects: 183
Study 11580089 — intervention group
Group type: EXPERIMENTAL
Intervention: OIDP in questionnaire format
Number of subjects: 183
Study 11580089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both questionnaires
Number of subjects: 183
Study 11580089 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP 14
Number of subjects: 183
Study 11580089 — intervention group
Group type: EXPERIMENTAL
Intervention: OIDP
Number of subjects: 183
Study 9853852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramesosalpingeal injection of 20 IU oxytocin diluted to 20 ml with saline solution
Number of subjects: 25
Study 9853852 — intervention group
Group type: COMPARATOR
Intervention: 20 ml saline solution (control)
Number of subjects: 25
Study 8014707 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-triggered, flow-synchronized ventilation
Number of subjects: 30
Study 8014707 — intervention group
Group type: COMPARATOR
Intervention: Conventional time-cycled, pressure-limited ventilation
Number of subjects: 30
Study 2687142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 339
Study 2687142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night (single dose)
Number of subjects: 339
Study 4559027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine
Number of subjects: 25
Study 4559027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31443993 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Administration group (RZV dose 1 and Tdap at Day 0, RZV dose 2 at Month 2)
Number of subjects: 0
Study 31443993 — intervention group
Group type: COMPARATOR
Intervention: Control group (Tdap at Day 0, RZV dose 1 at Month 2, RZV dose 2 at Month 4)
Number of subjects: 0
Study 31443993 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Administration group and Control group
Number of subjects: 0
Study 29216285 — intervention group
Group type: EXPERIMENTAL
Intervention: HI(R)T
Number of subjects: 80
Study 25026944 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner relationship focusing (20‐h course followed by 5 months of weekly sessions)
Number of subjects: 13
Study 25026944 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 23625433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/d for 5 days
Number of subjects: 12
Study 23625433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21803260 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrew between the premolar and the molar (Group A)
Number of subjects: 36
Study 21803260 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrew between the premolars (Group B)
Number of subjects: 36
Study 21803260 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 36
Study 19833787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 134
Study 19833787 — intervention group
Group type: COMPARATOR
Intervention: Structured clinical management (SCM)
Number of subjects: 134
Study 17091656 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SMP)
Number of subjects: 60
Study 17091656 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB)
Number of subjects: 60
Study 17091656 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSB)
Number of subjects: 60
Study 17091656 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (APL)
Number of subjects: 60
Study 14741680 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI-based training with feedback information about activation levels in the somatomotor cortex
Number of subjects: 0
Study 14741680 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving similar training without rtfMRI information
Number of subjects: 0
Study 11583750 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical nephrectomy plus interferon-alfa-based immunotherapy (5x10(6) IU/m(2) subcutaneously three times per week)
Number of subjects: 83
Study 11583750 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa alone
Number of subjects: 83
Study 11263387 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB regimen (2E3H3R3Z3/4H3R3)
Number of subjects: 0
Study 11263387 — intervention group
Group type: COMPARATOR
Intervention: SM regimen (2S3H3R3Z3/4H3R3)
Number of subjects: 0
Study 7869303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pamidronate
Number of subjects: 30
Study 7869303 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pamidronate
Number of subjects: 30
Study 7869303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2450722 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic chemotherapy with 5-FU via the recanalized umbilical vein in patients without liver metastases
Number of subjects: 3
Study 2450722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal adjuvant chemotherapy after resection of liver metastases
Number of subjects: 3
Study 2450722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy in patients with unresectable liver metastases
Number of subjects: 3
Study 31608968 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted training via a training website
Number of subjects: 62
Study 31608968 — intervention group
Group type: COMPARATOR
Intervention: Training guidebook with the same content as the website
Number of subjects: 62
Study 30249314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cottage cheese (CC) - 30 g of protein, 10 g of carbohydrate, 0 g of fat
Number of subjects: 10
Study 30249314 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein (CP) - isoenergetic/isonitrogenous liquid
Number of subjects: 10
Study 30249314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) - 0 kJ
Number of subjects: 10
Study 27163237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 243
Study 27163237 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.7 mg
Number of subjects: 243
Study 27163237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 243
Study 27163237 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 243
Study 25009252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic pain during locomotor adaptation task (capsaicin cream applied around the ankle) on Day 1
Number of subjects: 30
Study 25009252 — intervention group
Group type: COMPARATOR
Intervention: Pain-free locomotor adaptation task on Day 2
Number of subjects: 30
Study 22490095 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D training
Number of subjects: 73
Study 22490095 — intervention group
Group type: COMPARATOR
Intervention: 2D training
Number of subjects: 73
Study 20957010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 60
Study 20957010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 60
Study 20957010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine
Number of subjects: 60
Study 20957010 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 18624971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 307
Study 15983180 — intervention group
Group type: COMPARATOR
Intervention: Light physical activity
Number of subjects: 1004
Study 15983180 — intervention group
Group type: COMPARATOR
Intervention: Moderate-high physical activity
Number of subjects: 1004
Study 15983180 — intervention group
Group type: COMPARATOR
Intervention: Light physical activity (women)
Number of subjects: 1004
Study 15983180 — intervention group
Group type: COMPARATOR
Intervention: Moderate-high physical activity (women)
Number of subjects: 1004
Study 12463730 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (40 mg once daily)
Number of subjects: 18
Study 12463730 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 10367540 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1.000/1.250 mg/m2, administered on days 1, 8, 15 every 4 weeks)
Number of subjects: 18
Study 7478688 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day for 4 weeks, increased to 40 mg if no marked improvement after 4 weeks
Number of subjects: 22
Study 7478688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2110198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (200 mg orally four times per day)
Number of subjects: 11
Study 2110198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2110198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 11
Study 6108175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 18
Study 6108175 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study 31761854 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial rehabilitation exercise (60 minutes once a week for 12 weeks)
Number of subjects: 21
Study 31761854 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial rehabilitation exercise
Number of subjects: 21
Study 31761854 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 21
Study 29075862 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 18
Study 29075862 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 18
Study 27018464 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous use of oxytocin and Foley balloon
Number of subjects: 166
Study 27018464 — intervention group
Group type: COMPARATOR
Intervention: Sequential use of Foley balloon followed by oxytocin
Number of subjects: 166
Study 24946565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides (20 mg, three times a day for three months)
Number of subjects: 64
Study 24946565 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (0.75 mg kg-1 d-1, gradually reduced to 5 mg d-1)
Number of subjects: 64
Study 23297561 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative Tuina manipulations
Number of subjects: 126
Study 23297561 — intervention group
Group type: COMPARATOR
Intervention: Routine Tuina manipulations (Control)
Number of subjects: 126
Study 20376462 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-UVA-induced corneal collagen cross-linking (CXL)
Number of subjects: 127
Study 18657280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lekker Fit! intervention including professional physical education teacher, three PE classes per week, additional sport and play activities, fitness testing, classroom education on nutrition and active living, and parental involvement.
Number of subjects: 20
Study 18657280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention implemented).
Number of subjects: 20
Study 15813763 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Browsing Journal Club (WBJC)
Number of subjects: 107
Study 15813763 — intervention group
Group type: COMPARATOR
Intervention: Health news website (control)
Number of subjects: 107
Study 15813763 — intervention group
Group type: COMPARATOR
Intervention: Both groups (WBJC and control)
Number of subjects: 107
Study 12815309 — intervention group
Group type: EXPERIMENTAL
Intervention: 65%/65% tilt
Number of subjects: 57
Study 12815309 — intervention group
Group type: COMPARATOR
Intervention: 42%/42% tilt
Number of subjects: 57
Study 12815309 — intervention group
Group type: EXPERIMENTAL
Intervention: System impedance for Group 1
Number of subjects: 57
Study 12815309 — intervention group
Group type: EXPERIMENTAL
Intervention: System impedance for Group 2
Number of subjects: 57
Study 10601505 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily)
Number of subjects: 450
Study 10601505 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (800 mg every eight hours) plus zidovudine and lamivudine
Number of subjects: 450
Study 10601505 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz plus indinavir (1000 mg every eight hours)
Number of subjects: 450
Study 10601505 — intervention group
Group type: COMPARATOR
Intervention: Indinavir plus zidovudine and lamivudine
Number of subjects: 450
Study 10601505 — intervention group
Group type: EXPERIMENTAL
Intervention: All combinations
Number of subjects: 450
Study 10601505 — intervention group
Group type: COMPARATOR
Intervention: Indinavir and two nucleoside reverse‐transcriptase inhibitors
Number of subjects: 450
Study 10601505 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz and two nucleoside reverse‐transcriptase inhibitors
Number of subjects: 450
Study 8720308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbricus spencer, single oral dose of 500 mg
Number of subjects: 0
Study 8720308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbricus spencer, 1500 mg/d for one week
Number of subjects: 0
Study 8384953 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8384953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3698511 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at incremental rates (4, 10, 25, and 62.5 ng min‐1 kg‐1)
Number of subjects: 6
Study 3698511 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion
Number of subjects: 6
Study 3698511 — intervention group
Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 6
Study 3698511 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at highest rate
Number of subjects: 6
Study 29363115 — intervention group
Group type: EXPERIMENTAL
Intervention: Before the 2011 terrorist attacks in Norway
Number of subjects: 0
Study 29363115 — intervention group
Group type: EXPERIMENTAL
Intervention: After the 2011 terrorist attacks in Norway
Number of subjects: 0
Study 29363115 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both experiments
Number of subjects: 0
Study 29724537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetically modified brace (labeled as a prototype computerized brace)
Number of subjects: 18
Study 29724537 — intervention group
Group type: COMPARATOR
Intervention: Identical brace (not labeled as computerized)
Number of subjects: 18